New study shows zonisamide benefits for juvenile absence epilepsy
A new study has underlined the potential benefits that juvenile absence epilepsy patients can experience through treatment with zonisamide.
The French study from the Hopital Gui de Chauliac and the Centre Saint Paul-H Gastaut involved 13 patients who were successively treated with add-on zonisamide between 2006 and 2010. Safety and efficacy assessments were based on patient and caregiver reports taken every three months.
According to results published in the journal Epilepsy Research, the drug showed efficacy in reducing the prevalence of generalised tonic-clonic, myoclonic and absence seizures among patients in this group.
The researchers said: “This study provides evidence that add-on zonisamide is efficient and well-tolerated in adult patients with refractory juvenile absence epilepsy, even at high doses.”
Sold under the brand name Zonegran, the drug functions by stabilising electrical activity in the brain to prevent seizures from occurring. In the UK, it is approved for use in the treatment of partial epilepsy and secondarily generalised partial epilepsy.
Posted by Anne Brown